FTH Stock Faeth Therapeutics, Inc.
US · NasdaqCMLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Oncology platform catalysts and strong analyst targets create significant speculative upside.
Future value: $56.09 (+188.53%) · 6-12 months
Signal breakdown
- ▸Citi maintained Buy with a $55 target.
- ▾Below 50-day MA (-37.44%)
- ▸~189% upside to price target
Is FTH a buy right now?
Trend: FTH is trading below the 50-day average (-43.48%), RSI 78 — overbought territory, with a 3-month return of -41.59%.
Valuation & quality: Faeth Therapeutics, Inc. trades on forward P/E -4.6, price-to-book 2.51; fundamentals show net margin 0.0%, return on equity -195.3%.
Analyst consensus: 13 analysts have a mean 12-month price target of $55.38 (+229.1% vs the last close; range $40.00 – $70.00), consensus rating “strong buy”.
Our screen: ACCUMULATE (score 1) — Oncology platform catalysts and strong analyst targets create significant speculative upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +3.30% | -15.50% | -20.60% | +18.30% | +9.00% | +20.30% | -9.20% | -42.60% |
Fundamentals
Analyst price target
Technical signals
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Sector: Healthcare · Industry: Biotechnology · United States · 29 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.